GlassScriptPhysician profile
Robert I Weiner
NPI 1841270444
$5,584.35
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $353 · 2020: $2,237 · 2021: $48.28 · 2022: $39.36 · 2023: $89.69 · 2024: $2,817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,636 · Food and Beverage: $270.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,636.00 |
| Food and Beverage | $270.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $4,986.73 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $118.63 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $114.57 | 2019 | |
| Amarin Pharma, INC. | $76.82 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $48.92 | 2019 | |
| Lilly USA, LLC | $48.29 | 2019-2023 | Mounjaro |
| Kowa Pharmaceuticals America, INC. | $35.70 | 2019 | |
| Abbott Laboratories | $26.35 | 2023 | Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $24.71 | 2023 | Arexvy, Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $24.03 | 2022 | |
| Astellas Pharma US INC | $19.35 | 2023 | Veozah |
| Arbor Pharmaceuticals, INC. | $18.04 | 2019 | |
| Horizon Therapeutics Plc | $15.33 | 2022 | |
| Sanofi Pasteur INC. | $14.31 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $12.57 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Weiner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.